176 results on '"Conca V"'
Search Results
2. Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials
3. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience
4. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
5. ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients
6. A knowledge discovery framework to predict the N2O emissions in the wastewater sector
7. Keratitis secondary to Fusarium spp. in Spain 2012-2014
8. Queratitis secundaria a Fusarium spp. en España 2012-2014
9. Multidrug resistant Fusarium keratitis
10. Queratitis por Fusarium multirresistente
11. 413P Primary tumor resection (PTR) in metastatic colorectal cancer (mCRC) patients (pts) treated with upfront chemotherapy (CT) + bevacizumab (BEV): A pooled analysis of TRIBE and TRIBE2 studies
12. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study
13. 367P Prospective evaluation of emergent RAS and BRAF mutations in pre-treated metastatic colorectal cancer patients candidate to anti-EGFR re-treatment: Preliminary findings from the PARERE study
14. Improving the visualization of non-absorbable T-Flux® implants in deep sclerectomy. Colouring technique
15. Mejorando la visualización del implante no absorbible T-Flux® para esclerectomía profunda. Técnica de tinción
16. 534P Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
17. 533P First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
18. SO-36 An immune-related gene expression profile predicts the efficacy of adding atezolizumab to first-line FOLFOXIRI/bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study
19. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers
20. Changes in the Hyperreflective Bands of Outer Retinal Layers after Idiopathic Epiretinal Membrane Surgical Removal
21. 467P Monocyte to red blood cells ratio (MRR): an innovative haematologic prognostic parameter in FOLFIRI-aflibercept treated patients: A subgroup analysis from the DISTINCTIVE trial
22. 459P Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial
23. SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study
24. 571P Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
25. SMART-Plant_Long-term validation of PHA production potential from the sidestream of municipal WWTP at pilot scale
26. SO-27 Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
27. SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study
28. SO-22 Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study
29. PD-21 Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients
30. Integrating Cross-Border Acquisitions: A Process-oriented Approach
31. 108P Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): A translational analysis of the TRIPLETE trial.
32. 402MO Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
33. 447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study
34. O-18 Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study
35. SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study
36. Efficacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma
37. PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome
38. C01/106 AUTOIMMUNE MANIFESTATIONS IN SELECTED PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALPHA INTERFERON
39. 631P - PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome
40. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon
41. Angiocholographie intra-veineuse et cholangiographie rétrograde : rendement diagnostique individuel et cumulatif chez 170 patients
42. Colorectal cancer screening in LHU4 Chiavarese, Italy: ethical, methodological and outcome evaluations at the end of the first round
43. Colonoscopy practice in Italy: a prospective survey on behalf of the Italian Association of Hospital Gastroenterologists
44. Análisis del espesor de la capa de fibras nerviosas en niños de 6 a 9 años
45. Botulismo simultáneo en dos hermanos cocainómanos
46. Queratitis secundaria a Fusariumspp. en España 2012-2014
47. International Acquisitions: The Key to Success in the Experience of Italian companies
48. International Acquisitions:The Key to Success in the Experience of talian companies
49. Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use
50. Characterization of hepatitis C virus genotypes in Italian subjects at different risk of infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.